The global mammalian polyclonal IgG antibody market size reached US$ 1.09 billion in 2023. Looking forward, the publisher expects the market to reach US$ 1.64 billion by 2032, exhibiting a growth rate (CAGR) of 4.68% during 2023-2032.
Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations.
Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.
Moreover, the escalating biomarkers approval and their extensive usage by clinicians for accurate and rapid diagnosis of B-cell lymphoma and leukemia are supporting the market growth. Apart from this, significant enhancements in the healthcare infrastructure and research and development (R&D) activities to enhance antibody efficacy are creating a positive outlook for the market.
2. What is the expected growth rate of the global mammalian polyclonal IgG antibody market during 2024-2032?
3. What are the key factors driving the global mammalian polyclonal IgG antibody market?
4. What has been the impact of COVID-19 on the global mammalian polyclonal IgG antibody market?
5. What is the breakup of the global mammalian polyclonal IgG antibody market based on the type?
6. What is the breakup of the global mammalian polyclonal IgG antibody market based on the product?
7. What is the breakup of the global mammalian polyclonal IgG antibody market based on the application?
8. What is the breakup of the global mammalian polyclonal IgG antibody market based on the end use?
9. What are the key regions in the global mammalian polyclonal IgG antibody market?
10. Who are the key players/companies in the global mammalian polyclonal IgG antibody market?
Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations.
Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.
Mammalian Polyclonal IgG Antibody Market Trends:
The increasing prevalence of various chronic disorders, including cancer and autoimmune ailments, and the rising need for antibodies for multiple immunoassay tests and therapeutic and analytical applications in research settings are primarily driving the market growth. In line with this, significant investments in biotechnology and pharmaceutical companies by governments to formulate effective novel vaccinations and injectables through advanced technologies are acting as another growth-inducing factor. Additionally, the ongoing innovation of creative mammalian antibodies by biopharma organizations for quality control (QC) is contributing to the market growth.Moreover, the escalating biomarkers approval and their extensive usage by clinicians for accurate and rapid diagnosis of B-cell lymphoma and leukemia are supporting the market growth. Apart from this, significant enhancements in the healthcare infrastructure and research and development (R&D) activities to enhance antibody efficacy are creating a positive outlook for the market.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global mammalian polyclonal IgG antibody market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, product, application, and end use.Breakup by Type:
- Goat
- Rabbit
- Horse
- Mouse
- Others
Breakup by Product:
- Cardiac Markers
- Metabolic Markers
- Renal Markers
- Others
Breakup by Application:
- ELISA
- Immunoturbidimetry
- Immunoelectrophoresis
- Antibody Identification
- Immunohistochemistry
- Immunocytochemistry
- Western Blotting
Breakup by End Use:
- Hospitals
- Diagnostic Centers
- Academic and Research Institutes
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbiotec Inc., Abcam plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Creative Diagnostics, Elabscience Biotechnology Inc., Geno Technology Inc., Merck KGaA, Proteintech Group Inc., STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc.Key Questions Answered in This Report
1. How big is the global mammalian polyclonal IgG antibody market?2. What is the expected growth rate of the global mammalian polyclonal IgG antibody market during 2024-2032?
3. What are the key factors driving the global mammalian polyclonal IgG antibody market?
4. What has been the impact of COVID-19 on the global mammalian polyclonal IgG antibody market?
5. What is the breakup of the global mammalian polyclonal IgG antibody market based on the type?
6. What is the breakup of the global mammalian polyclonal IgG antibody market based on the product?
7. What is the breakup of the global mammalian polyclonal IgG antibody market based on the application?
8. What is the breakup of the global mammalian polyclonal IgG antibody market based on the end use?
9. What are the key regions in the global mammalian polyclonal IgG antibody market?
10. Who are the key players/companies in the global mammalian polyclonal IgG antibody market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Mammalian Polyclonal IgG Antibody Market
6 Market Breakup by Type
7 Market Breakup by Product
8 Market Breakup by Application
9 Market Breakup by End Use
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbiotec Inc.
- Abcam plc
- Bio-Rad Laboratories Inc.
- Cell Signaling Technology Inc.
- Creative Diagnostics
- Elabscience Biotechnology Inc.
- Geno Technology Inc.
- Merck KGaA
- Proteintech Group Inc.
- STEMCELL Technologies Inc.
- Thermo Fisher Scientific Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 1.09 Billion |
| Forecasted Market Value ( USD | $ 1.65 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
